| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | -0.49 | 0.0002 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0009 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.096 | 0.003 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.42 | 0.01 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | -0.4 | 0.01 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.078 | 0.01 |